Press release
Posted on October 3, 2023
“The chronic hepatitis B market is expected to emerge owing to rising prevalence and awareness of the disease during the forecast period (2023-2032). Additionally, the launch of various multi-chronic hepatitis B pipeline products will significantly transform chronic hepatitis B Hepatitis B Market Dynamics.”
The Chronic Hepatitis B market report provides current treatment practices, emerging drugs for Chronic Hepatitis B, market share of individual therapies, and current and forecasted Chronic Hepatitis B market size of 7MM from 2019 to 2032. The report also covers current Chronic Hepatitis B Treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the potential potential of the market.
Key Key Points of the Chronic Hepatitis B Market Research Report
- DelveInsight estimates that there will be approximately 3,04,900 and 53,800 cases of liver compensation and decompensation in Japan in 2022. These cases are expected to increase during the forecast period.
- In the United States, approximately 55% of cases are caused by the disease, and approximately 40% of women have chronic hepatitis B.
- Leading companies in the chronic hepatitis B market include Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Novartis, and others.
- Promising chronic hepatitis B pipeline therapies in various stages of development include tenofovir alafenamide, VIR-221, Selgantolimod, telbivudine, lamivudine, pegylated interferon-alpha 2a, and others .
- September 2023: Brii Biosciences Limited announced a Phase 2 clinical trial study of PEG-IFNα and BRII-835. This study will evaluate the efficacy and safety of PEG-IFNα alone or in combination with varying doses of BRII-835 (VIR-2218) in participants with chronic hepatitis B virus (HBV) infection.
- September 2023: Gilead Sciences announces Phase 1 clinical trials of GS-2829 and GS-6779. The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and those with chronic hepatitis B.
Learn more about therapies capturing key chronic hepatitis B market share @Chronic Hepatitis B Market Size
Overview of chronic hepatitis B
Chronic hepatitis B (CHB) is described as “a heterogeneous disease with markedly variable levels of viral replication and liver disease activity.” It is characterized by liver injury mediated by T cell immune responses directed against hepatocytes expressing viral antigens.
Epidemiological breakdown of chronic hepatitis B in 7MM
- Total number of prevalent cases of chronic hepatitis B
- Total number of confirmed prevalent cases of chronic hepatitis B
- Prevalent cases of chronic hepatitis B confirmed by gender
- Prevalence of confirmed chronic hepatitis B cases by age
- Confirmed prevalent cases of chronic hepatitis B
- Total number of chronic hepatitis B treated cases
Download the report to learn what factors are driving chronic hepatitis B epidemiology trends @Chronic Hepatitis B Epidemiology Insights
Listed drugs for chronic hepatitis B
- VEMLIDY (tenofovir alafenamide): Gilead Sciences
VEMLIDY is an HBV nucleoside analog reverse transcriptase inhibitor. It is approved for the treatment of chronic hepatitis B infection in adults and pediatric patients 12 years and older with compensated liver disease. Most recently, VEMLIDY was approved in the United States in November 2022 for the treatment of chronic hepatitis B infection in pediatric patients 12 years and older with compensated liver disease. However, the drug was approved first in the United States and Japan and subsequently in the European Union (2017) for the treatment of adults with chronic hepatitis B.
Emerging drugs for chronic hepatitis B
- Bepirovesan (GSK3228836): GlaxoSmithKline/Ionis Pharma
Bepirovirsen (GSK3228836) is an investigational antisense oligonucleotide (ASO) designed to specifically recognize the RNA used by the hepatitis B virus to replicate itself in infected liver cells (hepatocytes) and is manufactured by Viral antigens (proteins) that promote disease chronicity help avoid clearance by the immune system. The assets were licensed by GSK from Ionis Pharmaceuticals in August 2019.
To learn more about chronic hepatitis B treatment options, visit @chronichepatitisBdrugs
Chronic Hepatitis B Drug Market
The existing treatments for chronic hepatitis B mainly include antiviral drugs such as entecavir, VEMLIDY, VIREAD, telbivudine, adefovir dipivoxil, and lamivudine. Lamivudine is the first NA approved by the US FDA for the treatment of chronic hepatitis B. The drug was approved for adults in 1998 and pediatric approval in 2001 for children ages 2-17 years. But the drug has been used and licensed to treat HIV infection since 1995. It has few side effects and can be successfully used on a variety of patients. However, long-term lamivudine treatment results in significant resistance rates, leading to virological and biochemical relapse. Lamivudine is recommended as second-line therapy for the treatment of hepatitis B.
Chronic Hepatitis B Market Outlook
Chronic hepatitis B treatment in the United States is entering a new and dynamic era. To date, the US FDA has approved several drugs for the treatment of chronic hepatitis B: interferon-α and pegylated interferon-α, nucleoside analogs (NA), and nucleotide analog prodrugs. Oral antivirals include VIREAD (tenofovir disoproxil), VEMLIDY (tenofovir alafenamide), BARACLUDE (entecavir), TYZEKA or SEBIVO (telbivudine), HEPSERA (adefovir dipivoxil), and Lamivudine (Epivir-HBV, Zeffix, or Heptodin). The treatments listed above help fight the virus and slow its ability to damage the liver.
Learn more about the pipeline of chronic hepatitis B therapies in clinical trials @ Chronic Hepatitis B Market Landscape
Scope of Chronic Hepatitis B Market Report
- Coverage-7MM
- Study period – 2019-2032
- Chronic Hepatitis B Companies – Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Janssen Sciences Ireland, Assembly Biosciences, Janssen and Arrowhead Pharmaceuticals, Roche, Vir Biotechnology, Novartis and others.
- Chronic Hepatitis B Pipeline Therapies – Tenofovir Alafenamide, VIR-221, Selgantolimod, Telbivudine, Lamivudine, Pegylated Interferon-alpha 2a, and more.
- Chronic Hepatitis B Market Dynamics: Ataxia Telangiectasia Market Drivers and Barriers
- Chronic Hepatitis B Market Access and Reimbursement, Unmet Needs and Future Outlook
Learn more about chronic hepatitis B drugs in development @ Chronic Hepatitis B Ongoing Clinical Trial Analysis
Table of contents
1. Key insights
2. Introduction to the report
3. Chronic Hepatitis B Market Overview
4. Chronic Hepatitis B Executive Summary
5. Epidemiology and market methodology
6. Disease background and overview
7. Diagnosis of hepatitis B infection
8. Current Treatment Practices
9. Epidemiology and patient populations
10. Patient journey
11. Key Endpoints in Chronic Hepatitis B Clinical Trials
12. Marketed therapies
13. Emerging therapies
14. Medications to be discontinued
15. Chronic hepatitis B: 7MM analysis
16. Market access and reimbursement
17. KOL opinions
18.SWOT analysis
19. Unmet needs
20. Appendix
21.DelveInsight function
22. Disclaimer
23. About DelveInsight
about Us
DelveInsight is a business consulting and market research firm that provides professional business solutions to the healthcare sector and provides typical consulting services in the areas of research and development, strategy formulation, operations, competitive intelligence, healthcare market research reports, competitive landscape, and mergers and acquisitions .
Media Contact
Company Name: DelveInsight Business Research LLP
contact person: Yash Bhardwaj
e-mail: send email
Telephone: 9193216187
address:304 S. Jones Avenue #2432
City: las vegas
state: NV
nation: USA
website: https://www.delveinsight.com/consulting/ci-tracking